EyePoint Pharmaceuticals Management
Management criteria checks 2/4
EyePoint Pharmaceuticals' CEO is Jay Duker, appointed in Jan 2023, has a tenure of 1.33 years. total yearly compensation is $2.92M, comprised of 21.1% salary and 78.9% bonuses, including company stock and options. directly owns 0.1% of the company’s shares, worth $936.59K. The average tenure of the management team and the board of directors is 1.3 years and 3.4 years respectively.
Key information
Jay Duker
Chief executive officer
US$2.9m
Total compensation
| CEO salary percentage | 21.1% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.1% |
| Management average tenure | 1.3yrs |
| Board average tenure | 3.4yrs |
Recent management updates
Recent updates
More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%
Mar 31
EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time
Feb 20Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%
Feb 05Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?
Jan 29Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking
Dec 18These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Dec 13Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
May 14Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking
Apr 17EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space
Aug 30Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Jul 16EyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMD
Jul 15Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Mar 06EyePoint Pharmaceuticals (NASDAQ:EYPT) Is Using Debt Safely
Sep 24Estimating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Apr 02How Many EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Do Institutions Own?
Feb 22EyePoint Pharma announces potential capital raise
Feb 01EyePoint Pharmaceuticals reports prelim Q4 revenue; strong FY21 product outlook
Jan 11Ocumension Therapeutics invests $15.7M in EyePoint Pharma
Jan 04CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$3m | US$614k | -US$71m |
| Sep 30 2023 | n/a | n/a | -US$100m |
| Jun 30 2023 | n/a | n/a | -US$106m |
| Mar 31 2023 | n/a | n/a | -US$102m |
| Dec 31 2022 | US$2m | US$515k | -US$102m |
| Sep 30 2022 | n/a | n/a | -US$78m |
| Jun 30 2022 | n/a | n/a | -US$77m |
| Mar 31 2022 | n/a | n/a | -US$67m |
| Dec 31 2021 | US$3m | US$269k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$54m |
| Jun 30 2021 | n/a | n/a | -US$42m |
| Mar 31 2021 | n/a | n/a | -US$44m |
| Dec 31 2020 | US$53k | n/a | -US$45m |
| Sep 30 2020 | n/a | n/a | -US$40m |
| Jun 30 2020 | n/a | n/a | -US$52m |
| Mar 31 2020 | n/a | n/a | -US$51m |
| Dec 31 2019 | US$80k | n/a | -US$57m |
| Sep 30 2019 | n/a | n/a | -US$58m |
| Jun 30 2019 | n/a | n/a | -US$75m |
| Mar 31 2019 | n/a | n/a | -US$98m |
| Dec 31 2018 | US$27k | n/a | -US$86m |
| Sep 30 2018 | n/a | n/a | -US$80m |
| Jun 30 2018 | n/a | n/a | -US$53m |
| Mar 31 2018 | n/a | n/a | -US$25m |
| Dec 31 2017 | n/a | n/a | -US$23m |
| Sep 30 2017 | n/a | n/a | -US$17m |
| Jun 30 2017 | US$72k | n/a | -US$18m |
Compensation vs Market: Jay's total compensation ($USD2.92M) is about average for companies of similar size in the US market ($USD3.42M).
Compensation vs Earnings: Jay's compensation has increased whilst the company is unprofitable.
CEO
Jay Duker (64 yo)
1.3yrs
Tenure
US$2,915,146
Compensation
Dr. Jay S. Duker, M.D., co-founded Hemera Biosciences Inc. and serves as its Executive Director. He serves as Member of Retina Segment Scientific Advisory Board at Aldeyra Therapeutics, Inc. He served as C...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.3yrs | US$2.92m | 0.10% $ 936.6k | |
| Executive VP & CFO | 4.5yrs | US$1.78m | 0.084% $ 786.6k | |
| Interim Head of R&D and Director | less than a year | US$161.67k | 0.022% $ 205.7k | |
| Senior Vice President of Manufacturing & Operations | less than a year | no data | no data | |
| Chief Legal Officer & Company Secretary | 5.5yrs | no data | no data | |
| Chief People Officer & Senior VP of IT | 5.3yrs | no data | no data | |
| Senior VP & Chief Commercial Officer | 4.9yrs | US$1.46m | 0.086% $ 810.3k | |
| Chief Business Officer | less than a year | US$1.61m | 0.026% $ 246.5k | |
| Chief Regulatory Officer | 2.2yrs | no data | no data | |
| Senior Vice President of Program Leadership | less than a year | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data | |
| CEO of AION Diagnostics Ltd | no data | US$225.94k | no data |
1.3yrs
Average Tenure
57yo
Average Age
Experienced Management: EYPT's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | US$2.92m | 0.10% $ 936.6k | |
| Interim Head of R&D and Director | 5.6yrs | US$161.67k | 0.022% $ 205.7k | |
| CEO of AION Diagnostics Ltd | no data | US$225.94k | no data | |
| Independent Non-Executive Chairman | 5.9yrs | US$214.78k | 0.016% $ 147.0k | |
| Independent Director | 4.8yrs | US$171.67k | 0.014% $ 133.5k | |
| Executive Vice-Chairman | 7.7yrs | US$3.74m | 0.40% $ 3.8m | |
| Independent Director | 5.3yrs | US$180.67k | 0.014% $ 133.5k | |
| Co- Chairman of Scientific Advisory Board | 2.8yrs | no data | no data | |
| Member of Executive Scientific Advisory Board | 2.8yrs | no data | no data | |
| Co-Chair of Scientific Advisory Board | 2.8yrs | no data | no data | |
| Director | 3.4yrs | no data | no data | |
| Member of Executive Scientific Advisory Board | 2.8yrs | no data | no data |
3.4yrs
Average Tenure
64yo
Average Age
Experienced Board: EYPT's board of directors are considered experienced (3.4 years average tenure).